首页 | 本学科首页   官方微博 | 高级检索  
检索        

甘氨双唑钠联合同期放化疗治疗局部中晚期食管癌的临床观察
引用本文:鹿红,赵迪,于大海,马珺,张碧云,宋威.甘氨双唑钠联合同期放化疗治疗局部中晚期食管癌的临床观察[J].临床肿瘤学杂志,2014,19(10):921-924.
作者姓名:鹿红  赵迪  于大海  马珺  张碧云  宋威
作者单位:210029.南京江苏省中医院放疗科
摘    要:目的 比较甘氨双唑钠(CMNa)联合同步放化疗(CRT)治疗局部中晚期食管癌的疗效和毒副反应。方法 2012年6月至2013年11月87例食管癌患者采用信封法随机分为CMNa+CRT组(n=44)和CRT组(n=43)。调强放疗采用6 MV直线加速器,2.0Gy/次,每周5次,DT 50Gy。CMNa+CRT组放疗前0~3h给予CMNa 800mg/m2静滴,每周1、3、5给药,直至放疗结束。化疗采用顺铂(DDP)+氟尿嘧啶(5-FU)方案:DDP 125mg/m2静滴,d1~d5;5-FU 450mg/m2静滴,d1~d5,28天为1周期, 共2个周期。结果 87例患者均可评价疗效。CMNa+CRT组获CR 31例,PR 8例,SD 4例,PD 1例,有效率为907%;CRT组获CR 25例,PR 7例,SD 9例,PD 2例,有效率为744%,两组有效率的差异有统计学意义(P=0043)。两组毒副反应主要为1~2级骨髓抑制、肝功能异常、放射性食管炎和放射性肺炎,差异无统计学意义(P>0.05)。CMNa+CRT组和CRT组的1年生存率分别为900%和833%,差异无统计学意义(P>0.05)。结论 CMNa联合CRT治疗局部中晚期食管癌具有增敏作用,且不增加近期毒副反应。

关 键 词:甘氨双唑钠  同步放化疗  食管癌
收稿时间:2014-03-14
修稿时间:2014-07-19

Clinical observation of sodium glycididazole combined with concurrent radiochemotherapy for locally ad-vanced esophageal cancer
LU Hong,ZHAO Di,YU Dahai,MA Jun,ZHANG Biyun,SONG Wei.Clinical observation of sodium glycididazole combined with concurrent radiochemotherapy for locally ad-vanced esophageal cancer[J].Chinese Clinical Oncology,2014,19(10):921-924.
Authors:LU Hong  ZHAO Di  YU Dahai  MA Jun  ZHANG Biyun  SONG Wei
Institution:Department of Radiotherapy, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing 210029, China
Abstract:Objective To evaluate the efficacy and side effects of sodium glycididazole( CMNa) combined with concurrent ra-diochemotherapy(CRT) for locally advanced esophageal cancer. Methods From June 2012 to November 2013, 87 patients pathologically confirmed as esophageal cancer were randomized into CMNa+CRT group(n=44) and CRT group(n=43). Radiotherapy was given by 6 MV X-ray on conventional schedule(2. 0Gy/f, 5 fractions a week, DT 50Gy). CMNa was given intravenously 800mg/m2, every Monday, Wednesday and Friday 0-3h before radiation. Chemotherapy regimen contained cisplatin 12. 5mg/m2 iv d1-d5 , and fluorouracil 450mg/m2 iv d1-d5 with 28 days of a cycle for 2 cycles. Results All patients were evaluable. Patients in CMNa+CRT group achieved 31 CR, 8 PR, 4 SD, 1 PD, and responce rate(RR) was 90. 7%;While in CRT group,patients got 25 CR,7 PR, 9 SD, 2 PD, and RR was 74. 4%. There were significant differences between RR of the two groups(P=0. 043). Main side effects were grade 1-2 bone marrow inhibition, hepatic dyfunction, radioactive esophagitis and radioactive pneumonia, with no differences(P〉0. 05).The 1-year survival rates were 90. 0% and 83. 3% in CMNa+CRT group and CRT group with no differences( P〉0. 05) . Conclusion CMNa combined with CRT for lo-cally advanced esophageal cancer can improve healing efficacy obviously and do not cause severe side effects.
Keywords:Sodium glycididazole( CMNa)  Concurrent radiochemotherapy  Esophageal cancer
本文献已被 维普 等数据库收录!
点击此处可从《临床肿瘤学杂志》浏览原始摘要信息
点击此处可从《临床肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号